Impact Biomedical vs Lyell Immunopharma
Impact Biomedical and Lyell Immunopharma are similar in size: $32,000 and $36,000 of revenue in their latest fiscal years. Impact Biomedical grew faster (-36.0% against -41.0%). Impact Biomedical kept more of each dollar of sales as profit: a net margin of -36993.8% against -762355.6%. Impact Biomedical carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Impact BiomedicalIBO, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $32,000 | $36,000 |
| Revenue growth | -36.0% | -41.0% |
| Net income | −$11.8m | −$274m |
| Operating margin | -13381.3% | -748344.4% |
| Net margin | -36993.8% | -762355.6% |
| Return on equity | -56.5% | -87.0% |
| Free cash flow | — | −$151m |
| Cash | $3,000 | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 161 |
| Market value | $436m | $252m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 6 sales | 2 buys, 29 sales |